ACTRN12606000007538进行中（未招募）1 期
A phase 1/2 study to test the safety and efficacy of a single implantation of SIR-Spheres plus systemic chemotherapy with FOLFOX4 in patients with liver metastases derived from colorectal carcinoma.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Histologically confirmed adenocarcinoma of the colon or rectum. CT evidence of malignant metastases in the liver. Liver metastases not treatable by some other form of local ablation. Prior treatment for metastatic CRC is not allowedAdequate hepatic, renal and haematological functionWHO performance status 0-2Willing and able to provide written informed consent.
排除标准
- •Pregnant or breast feedingEvidence of ascites, cirrhosis or portal hypertensionCNS metastases Previous radiotherapy to the upper abdomenNon-malignant disease that would render the patient ineligible for treatmentEquivocal, immeasurable or unevaluable metastases in the liverHepatic arterial anatomy that would prevent administration of SIR-Spheres>20% arteriovenous lungshuntingDLT associated with previous 5FU chemotherapy.
研究者
相似试验
进行中（未招募）
1 期
A phase II study of second line therapy on safety and efficacy of nintedanib for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.Histologically confirmed differentiated or medullary thyroid cancer by local pathologist.MedDRA version: 17.0Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004295-19-FREuropean Organisation for Research and Treatment of Cancer. EORTC102
进行中（未招募）
1 期
A phase II study of second line therapy on safety and efficacy of nintedanib for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.EUCTR2012-004295-19-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)102
进行中（未招募）
1 期
A phase II study of second line therapy on safety and efficacy of nintedanib for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.EUCTR2012-004295-19-DKEuropean Organisation for Research and Treatment of Cancer (EORTC)142
已完成
2 期
A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with eitherc differentiated and medullary thyroid carcinoma progressing after first line therapy.thyroid carcinomathyroid cancer10043739NL-OMON47685European Organisation for Research in Treatment of Cancer (EORTC)15
进行中（未招募）
1 期
A phase II study of second line therapy on safety and efficacy of nintedanib for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.Histologically confirmed differentiated or medullary thyroid cancer by local pathologist.MedDRA version: 21.1Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004295-19-GBEuropean Organisation for Research and Treatment of Cancer (EORTC)102